CANTA.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:29):

Stats
Dzisiejszy wolumen	187 738
Średni wolumen	570 691
Kapitalizacja rynkowa	570.76M
EPS	SEK0 ( 2024-02-21 )
Następna data zysków	( SEK0 ) 2024-05-21
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.540
ATR14	SEK0.00500 (0.15%)

Wolumen Korelacja

Długi: -0.14 (neutral)

Krótki: -0.54 (weak negative)

Signal:(47.564) Neutral

Cantargia AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cantargia AB (publ) Korelacja - Waluta/Towar

0.10
( neutral )

0.11
( neutral )

0.00
( neutral )

0.16
( neutral )

-0.47
( neutral )

-0.26
( neutral )

Cantargia AB (publ) Finanse

Annual	2023
Przychody:	SEK0
Zysk brutto:	SEK-3.45M (0.00 %)
EPS:	SEK-1.650

FY	2023
Przychody:	SEK0
Zysk brutto:	SEK-3.45M (0.00 %)
EPS:	SEK-1.650

FY	2022
Przychody:	SEK0
Zysk brutto:	SEK-3.69M (0.00 %)
EPS:	SEK-2.83

FY	2021
Przychody:	SEK0.00
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-3.05

Financial Reports:

No articles found.

Cantargia AB (publ)

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.